Patent Application
20210380613
The present specification generally relates to methods for preparing borane complexes from aryldihalophosphines. In particular, the present specification is directed to methods for preparing borane complexes from aryldihalophosphines with a solution comprising sodium borohydride.
Arylphosphines have potential uses as raw materials to commercial ligands in transition metal catalysis. However, phosphines are prone to oxidation and/or combustion, which make them dangerous to transport and handle. Accordingly, intermediary complexes of arylphosphines are formed that are less dangerous to transport and handle. The intermediary complexes can either be used in place of arylphosphines, or the intermediary complexes can be converted back to arylphosphines when they have safely been transported and/or handled. Intermediary complexes of arylphosphines that have been particularly useful are borane complexes of arylphosphines.
Unfortunately, known methods for preparing arylphosphines-borane complexes typically require borane reagents for production of arylphosphine-borane complexes.
According to embodiments, methods for preparing phosphine-borane complexes from aryldihalophosphine comprise: mixing sodium borohydride (NaBH4), a solvent comprising at least 50 volume percent (vol %) glycol ethers, and the aryldihalophosphine to obtain a solution; and maintaining the solution at a reaction temperature for a duration of time to obtain the phosphine-borane complexes.
According to embodiments, the glycol ethers comprises 1,2-dimethoxyethane, and in some embodiments, the solvent further comprises tetrahydrofuran. In further embodiments, a ratio of tetrahydrofuran to 1,2-dimethoxyethane in the solvent comprising may be from 0.1:1.0 to 2.5:1.0. In some embodiments, a ratio of sodium borohydride to aryldihalophosphine is from 1.1:1.0 to 2.5:1.0.
Additional features and advantages will be set forth in the detailed description which follows, and in part will be readily apparent to those skilled in the art from that description or recognized by practicing the embodiments described herein, including the detailed description which follows and the claims.
It is to be understood that both the foregoing general description and the following detailed description describe various embodiments and are intended to provide an overview or framework for understanding the nature and character of the claimed subject matter. The accompanying drawings are included to provide a further understanding of the various embodiments, and are incorporated into and constitute a part of this specification.
Common abbreviations are listed below:
BH3.THF: borane tetrahydrofuran complex; BH3.SMe2: borane dimethyl sulfide; NaBH4: sodium borohydride; DME: 1,2-dimethoxyethane; THF: tetrahydrofuran; CDCl3; deuterated chloroform; ZnCl2: zinc chloride; s: seconds; ppm: parts per million; Hz: hertz; μsec: microseconds; mm: millimeter; g: gram; mmol: millimolar; and mL: milliliter.
Aryl phosphine borane complexes are generally prepared in two steps: (1) reduction of an aryldichlorophosphine to a phosphine; and (2) subsequent reaction with a borane source such as borane tetrahydrofuran complex (BH3.THF) or borane dimethyl sulfide (BH3.SMe2). However, these preparations are challenging for scale-up because of the instability of the BH3.THF complex and the release of SMe2 from the BH3—SMe2 complex. Another preparation route that has been considered and is used to form borane complexes with some phosphines include using sodium borohydride (NaBH4). However, the use of NaBH4 to reduce aryldihalophosphines is complicated by: (1) the insolubility of NaBH4 in most aprotic solvents; and (2) the susceptibility of solvolysis of aryldihalophosphines by protic solvents. Additionally, common uses of NaBH4 are able to utilize all of the reducing equivalents of BH4−, but it is has been found herein that for aryldihalophosphines, that two molar equivalents of BH4− are required to fully reduce the aryldihalophosphine, suggesting that only one hydride equivalent is used for each BH4− molecule. Taking these considerations into account, methods for preparing phosphine-borane complexes from aryldihalophosphine according to embodiments disclosed and described herein comprise: mixing sodium borohydride (NaBH4), a solvent comprising at least 50 vol % glycol ethers, and the aryldihalophosphine to obtain a solution; and maintaining the solution at a reaction temperature for a duration of time to obtain the phosphine-borane complexes.
As disclosed above, methods for preparing phosphine-borane complexes from aryldihalophosphine according to embodiments comprises mixing NaBH4 and the aryldihalophosphine in a solvent comprising 50 vol % glycol ethers. The NaBH4 used in methods for preparing phosphine-borane complexes is not limited and can be commercially available NaBH4. In some embodiments, the NaBH4 is powdered NaBH4 with a purity greater than 98%, such as greater than 99%. The aryldihalophosphine that is mixed with NaBH4 to form an arylphosphine-borane complex may be, in embodiments, an aryldichlorophosphine, such as, for example, an aryldichlorophosphine selected from the group consisting of dichloro(2,4-dimethoxyphenyl)phosphine, dichloro(2-methoxyphenyl)phosphine, and dichlorophenylphosphine. In some embodiments, the aryldihalophosphine may be a mono-aryldihalophosphine, such as, for example, mono-aryldichlorophosphine. The solvent used to prepare phosphine-borane complexes from aryldihalophosphine is, in embodiments, of particular importance. For instance, THF is a solvent that is commonly used to form phosphine-borane complexes. Traditionally, THF is used as the sole solvent for preparing phosphine-borane complexes. However, it was found that a solvent comprising THF alone will not produce a phosphine-borane complex with NaBH4 and aryldihalophosphine, such as, for example, aryldichlorophosphine. The solution to this issue is not readily ascertainable. For example, Lam, Hubert et al., Mild Reduction of Chlorophosphine Boranes to Secondary Phosphine Boranes, 44 Tetrahedron Letters, 5213-5216 (2003) discloses that a preformed chlorophosphine-borane complex, generated by mixing the chlorophospine and BH3.THF, produced a phosphine-borane complex by mixing NaBH4 and diarylmonohalophosphine-borane complex in a solvent that only comprises THF (i.e., solvent is 100 vol % THF). However, as disclosed above, NaBH4 and aryldihalophosphine will not form a phosphine-borane complex in a solvent that only comprises THF. This indicates that the chemistry involved in forming the phosphine-borane complexes with NaBH4 and phosphines is complex and highly dependent on the structure of the phosphine and the composition of the solvent. Embodiments of methods for preparing phosphine-borane complexes from aryldihalophosphine disclosed and described herein address this issue, and provide methods for forming phosphine-borane complexes from aryldihalophosphine and NaBH4.
According to embodiments, a phosphine-borane complex is prepared by mixing NaBH4 and aryldihalophosphine in a solvent. According to some embodiments, a desired phosphine-borane complex may be formed by mixing NaBH4 and aryldihalophosphine at an appropriate ratio. Without being bound to any particular theory, if not enough NaBH4 is added to the solvent, phosphine-borane complexes will not be formed. However, if too much NaBH4 is added to the solvent, undesired byproducts may be formed, and additional NaBH4 must be separated from the product. According to some embodiments, a ratio of NaBH4 to aryldichlorophosphine is from 1.1:1.0 to 2.5:1.0, such as from 1.2:1.0 to 2.5:1.0, from 1.3:1.0 to 2.5:1.0, from 1.4:1.0 to 2.5:1.0, from 1.5:1.0 to 2.5:1.0, from 1.6:1.0 to 2.5:1.0, from 1.7:1.0 to 2.5:1.0, from 1.8:1.0 to 2.5:1.0, from 1.9:1.0 to 2.5:1.0, from 2.0:1.0 to 2.5:1.0, from 2.1:1.0 to 2.5:1.0, from 2.2:1.0 to 2.5:1.0, from 2.3:1.0 to 2.5:1.0, or from 2.4:1.0 to 2.5:1.0. In embodiments a ratio of NaBH4 to aryldichlorophosphine is from 1.1:1.0 to 2.4:1.0, such as from 1.1:1.0 to 2.3:1.0, from 1.1:1.0 to 2.2:1.0, from 1.1:1.0 to 2.1:1.0, from 1.1:1.0 to 2.0:1.0, from 1.1:1.0 to 1.9:1.0, from 1.1:1.0 to 1.8:1.0, from 1.1:1.0 to 1.7:1.0, from 1.1:1.0 to 1.6:1.0, from 1.1:1.0 to 1.5:1.0, from 1.1:1.0 to 1.4:1.0, from 1.1:1.0 to 1.3:1.0, or from 1.1:1.0 to 1.2:1.0. In embodiments, a ratio of NaBH4 to aryldichlorophosphine is from 1.2:1.0 to 2.4:1.0, such as from 1.3:1.0 to 2.3:1.0, from 1.4:1.0 to 2.2:1.0, from 1.5:1.0 to 2.1:1.0, from 1.6:1.0 to 2.0:1.0, or from 1.7:1.0 to 1.9:1.0. In embodiments, a ratio of NaBH4 to aryldichlorophosphine is from 1.5:1.0 to 2.2:1.0, such as from 1.6:1.0 to 2.1:1.0, from 1.7:1.0 to 2.0:1.0, or from 1.8:1.0 to 1.9:1.0.
Methods for preparing phosphine-borane complexes from aryldihalophosphine according to embodiments disclosed and described herein comprises mixing NaBH4 and aryldihalophosphine in a solvent comprising at least 50 vol % glycol ethers, such as at least 55 vol % glycol ethers, at least 60 vol % glycol ethers, at least 65 vol % glycol ethers, at least 70 vol % glycol ethers, at least 75 vol % glycol ethers, at least 80 vol % glycol ethers, at least 85 vol % glycol ethers, at least 90 vol % glycol ethers, or at least 95 vol % glycol ethers. According to some embodiments, the glycol ethers in the solvent may comprise 1,2-dimethoxyethane (DME), triglyme, diglyme, or mixtures thereof. In some embodiments, the glycol ethers in the solvent comprise DME. Accordingly, in some embodiments, the solvent in which NaBH4 and aryldihalophosphine is mixed may comprise at least 50 vol % DME, such as at least 55 vol % DME, at least 60 vol % DME, at least 65 vol % DME, at least 70 vol % DME, at least 75 vol % DME, at least 80 vol % DME, at least 85 vol % DME, at least 90 vol % DME, or at least 95 vol % DME.
As is apparent from the disclosure above, the solvent in which NaBH4 and aryldihalophosphine are mixed may, in embodiments, comprise components other than glycol ethers. According to some embodiments, the solvent in which NaBH4 and aryldihalophosphine are mixed may comprise tetrahydrofuran (THF), toluene, or mixtures thereof. In embodiments, the solvent may comprise from 5 vol % to 50 vol % THF, such as from 10 vol % to 50 vol % THF, from 15 vol % to 50 vol % THF, from 20 vol % to 50 vol % THF, from 25 vol % to 50 vol % THF, from 30 vol % to 50 vol % THF, from 35 vol % to 50 vol % THF, from 40 vol % to 50 vol % THF, or from 45 vol % to 50 vol % THF. In some embodiments, the solvent may comprise from 5 vol % to 45 vol % THF, such as from 5 vol % to 40 vol % THF, from 5 vol % to 35 vol % THF, from 5 vol % to 30 vol % THF, from 5 vol % to 25 vol % THF, from 5 vol % to 20 vol % THF, from 5 vol % to 15 vol % THF, or from 5 vol % to 10 vol % THF. In embodiments, the solvent may comprise from 10 vol % to 45 vol % THF, such as from 15 vol % to 40 vol % THF, from 20 vol % to 35 vol % THF, or from 25 vol % to 30 vol % THF.
In one or more embodiments, the solvent in which NaBH4 and aryldihalophosphine are mixed may comprise a mixture of DME and THF. In such embodiments, the solvent in which NaBH4 and aryldihalophosphine is mixed comprises a ratio of THF to DME from 0.1:1.0 to 2.5:1.0, such as from 0.2:1.0 to 2.5:1.0, from 0.3:1.0 to 2.5:1.0, from 0.4:1.0 to 2.5:1.0, from 0.5:1.0 to 2.5:1.0, from 0.6:1.0 to 2.5:1.0, from 0.7:1.0 to 2.5:1.0, from 0.8:1.0 to 2.5:1.0, from 0.9:1.0 to 2.5:1.0, from 1.0:1.0 to 2.5:1.0, from 1.1:1.0 to 2.5:1.0, from 1.2:1.0 to 2.5:1.0, from 1.3:1.0 to 2.5:1.0, from 1.4:1.0 to 2.5:1.0, from 1.5:1.0 to 2.5:1.0, from 1.6:1.0 to 2.5:1.0, from 1.7:1.0 to 2.5:1.0, from 1.8:1.0 to 2.5:1.0, from 1.9:1.0 to 2.5:1.0, from 2.0:1.0 to 2.5:1.0, from 2.1:1.0 to 2.5:1.0, from 2.2:1.0 to 2.5:1.0, from 2.3:1.0 to 2.5:1.0, or from 2.4:1.0 to 2.5:1.0. In some embodiments, the solvent in which NaBH4 and aryldihalophosphine is mixed comprises a ratio of THF to DME from 0.1:1.0 to 2.4:1.0, such as from 0.1:1.0 to 2.3:1.0, from 0.1:1.0 to 2.2:1.0, from 0.1:1.0 to 2.2:1.0, from 0.1:1.0 to 2.1:1.0, from 0.1:1.0 to 2.0:1.0, from 0.1:1.0 to 1.9:1.0, from 0.1:1.0 to 1.8:1.0, from 0.1:1.0 to 1.7:1.0, from 0.1:1.0 to 1.6:1.0, from 0.1:1.0 to 1.5:1.0, from 0.1:1.0 to 1.4:1.0, from 0.1:1.0 to 1.3:1.0, from 0.1:1.0 to 1.2:1.0, from 0.1:1.0 to 1.1:1.0, from 0.1:1.0 to 1.0:1.0, from 0.1:1.0 to 0.9:1.0, from 0.1:1.0 to 0.8:1.0, from 0.1:1.0 to 0.7:1.0, from 0.1:1.0 to 0.6:1.0, from 0.1:1.0 to 0.5:1.0, from 0.1:1.0 to 0.4:1.0, from 0.1:1.0 to 0.3:1.0, or from 0.1:1.0 to 0.2:1.0. In one or more embodiments, the solvent in which NaBH4 and aryldihalophosphine is mixed comprises a ratio of THF to DME from 0.2:1.0 to 2.4:1.0, such as from 0.3:1.0 to 2.3:1.0, from 0.4:1.0 to 2.2:1.0, from 0.5:1.0 to 2.1:1.0, from 0.6:1.0 to 2.0:1.0, from 0.7:1.0 to 1.9:1.0, from 0.8:1.0 to 1.8:1.0, from 0.9:1.0 to 1.7:1.0, from 1.0:1.0 to 1.6:1.0, from 1.1:1.0 to 1.5:1.0, or from 1.2:1.0 to 1.4:1.0. In embodiments, the solvent in which NaBH4 and aryldihalophosphine is mixed comprises a ratio of THF to DME from 0.1:1.0 to 1.0:1.0, such as from 0.2:1.0 to 0.9:1.0, from 0.3:1.0 to 0.8:1.0, from 0.4:1.0 to 0.7:1.0, or from 0.5:1.0 to 0.7:1.0.
According to embodiments, NaBH4 and aryldihalophosphine may be mixed by adding each as a dry component to a solvent that comprises at least 50 vol % glycol ethers. In some embodiments, NaBH4 may be added to a first solvent to form a first suspension, and aryldihalophosphine may be added to a second solvent to form a second suspension. In such embodiments, the first suspension and the second suspension are combined, which results in mixing the NaBH4 and aryldihalophosphine. In various embodiments, the first solvent and the second solvent may be the same or different. In embodiments where the first solvent and the second solvent are the same, each of the first solvent and the second solvent may comprise at least 50 vol % glycol ethers so that when the first suspension and the second suspension are combined, the combined solvent comprises at least 50 vol % glycol ethers. In embodiments where the first solvent and the second solvent are different, the composition of the first solvent and the composition of the second solvent should be formulated such that when the first suspension and the second suspension are combined, the combined solvent comprises at least 50 vol % glycol ethers. It should be understood that a skilled artisan is capable of formulating the first solvent and the second solvent so that when the first suspension and the second suspension are combined, the combined solvent comprises at least 50 vol % glycol ethers. Thus, in one or more embodiments, at least one of the first solvent and/or the second solvent comprises at least 50 vol % glycol ethers. In some embodiments, at least one of the first solvent and/or the second solvent may comprise THF. In embodiments, where one of the first solvent and/or the second solvent comprises THF and one of the first solvent or the second solvent comprises DME, the first solvent and the second solvent may be formulated to yield the THF to DME ratios disclosed herein.
As disclosed above, embodiments of methods for preparing phosphine borane complexes disclosed and described herein comprise mixing NaBH4 and aryldihalophosphine in a solvent comprising at least 50 vol % glycol ethers to obtain a solution, and maintaining the solution at a reaction temperature. In embodiments, the reaction temperature may be from 0° C. to 60° C., such as from 5° C. to 60° C., from 10° C. to 60° C., from 15° C. to 60° C., from 20° C. to 60° C., from 25° C. to 60° C., from 30° C. to 60° C., from 35° C. to 60° C., from 40° C. to 60° C., from 45° C. to 60° C., from 50° C. to 60° C., or from 55° C. to 60° C. In some embodiments, the reaction temperature may be from 0° C. to 55° C., such as from 0° C. to 50° C., from 0° C. to 45° C., from 0° C. to 40° C., from 0° C. to 35° C., from 0° C. to 30° C., from 0° C. to 25° C., from 0° C. to 20° C., from 0° C. to 15° C., from 0° C. to 10° C., or from 0° C. to 5° C. In embodiments, the reaction temperature may be from 5° C. to 55° C., such as from 10° C. to 50° C., from 15° C. to 45° C., from 20° C. to 40° C., or from 20° C. to 35° C.
In some embodiments, the solvent may be adjusted to the reaction temperature before NaBH4 and/or aryldihalophosphine is added to the solvent. In embodiments, NaBH4 and/or aryldihalophosphine may be added to the solvent at ambient temperature and the mixture of NaBH4, aryldihalophosphine, and solvent are adjusted to the reaction temperature. In embodiments, NaBH4 is added to a first solvent to form a first suspension and aryldihalophosphine is added to a second solvent to form a second suspension, the first solvent and/or the second solvent may be adjusted to the reaction temperature before the NaBH4 and/or aryldihalophosphine is added to the first solvent and/or second solvent, respectively. In some embodiments, NaBH4 is added to a first solvent at ambient temperature to form a first suspension and/or aryldihalophosphine is added to a second solvent at ambient temperature to form a second suspension, and the first suspension and/or the second suspension may be adjusted to the reaction temperature after the NaBH4 and/or aryldihalophosphine is added to the first solvent and/or second solvent, respectively. In some embodiments, NaBH4 is added to a first solvent at ambient temperature to form a first suspension and/or aryldihalophosphine is added to a second solvent at ambient temperature to form a second suspension, the first suspension and the second suspension may be combined at ambient temperature to form a combined solution, and the combined solution may be adjusted to the reaction temperature. The temperature of any of the solvents or suspensions disclosed herein may be adjusted to the reaction temperature by any suitable mechanism for adjusting the temperature of solutions or suspensions.
As disclosed herein, according to embodiments for preparing phosphine-borane complexes from aryldihalophosphine, the solution comprising NaBH4, aryldihalophosphine, and a solvent comprising at least 50 vol % glycol ethers is maintained at the reaction temperature for a duration of time. In embodiments, the duration of time is from 0.05 hours to 12.00 hours, such as from 0.10 hours to 12.00 hours, from 0.50 hours to 12.00 hours, from 1.00 hours to 12.00 hours, from 1.50 hours to 12.00 hours, from 2.00 hours to 12.00 hours, from 2.50 hours to 12.00 hours, from 3.00 hours to 12.00 hours, from 3.50 hours to 12.00 hours, from 4.00 hours to 12.00 hours, from 4.50 hours to 12.00 hours, from 5.00 hours to 12.00 hours, from 5.50 hours to 12.00 hours, from 6.00 hours to 12.00 hours, from 6.50 hours to 12.00 hours, from 6.50 hours to 12.00 hours, from 7.00 hours to 12.00 hours, from 7.50 hours to 12.00 hours, from 8.00 hours to 12.00 hours, from 8.50 hours to 12.00 hours, from 9.00 hours to 12.00 hours, from 9.50 hours to 12.00 hours, from 10.00 hours to 12.00 hours, from 10.50 hours to 12.00 hours, from 11.00 hours to 12.00 hours, or from 11.50 hours to 12.00 hours. In some embodiments, the duration of time is from 0.05 hours to 11.50 hours, such as from 0.05 hours to 11.00 hours, from 0.05 hours to 10.50 hours, from 0.05 hours to 10.00 hours, from 0.05 hours to 9.50 hours, from 0.05 hours to 9.00 hours, from 0.05 hours to 8.50 hours, from 0.05 hours to 8.00 hours, from 0.05 hours to 7.50 hours, from 0.05 hours to 7.00 hours, from 0.05 hours to 6.50 hours, from 0.05 hours to 6.00 hours, from 0.05 hours to 5.50 hours, from 0.05 hours to 5.00 hours, from 0.05 hours to 4.50 hours, from 0.05 hours to 4.00 hours, from 0.05 hours to 3.50 hours, from 0.05 hours to 3.00 hours, from 0.05 hours to 2.50 hours, from 0.05 hours to 2.00 hours, from 0.05 hours to 1.50 hours, from 0.05 hours to 1.00 hours, from 0.05 hours to 0.50 hours, or from 0.05 hours to 0.10 hours. In embodiments, the duration of time is from 0.10 hours to 11.50 hours, such as from 0.50 hours to 11.00 hours, from 1.00 hours to 10.50 hours, from 1.50 hours to 10.00 hours, from 2.00 hours to 9.50 hours, from 2.50 hours to 9.00 hours, from 3.00 hours to 8.50 hours, from 3.50 hours to 8.00 hours, from 4.00 hours to 7.50 hours, from 4.50 hours to 7.00 hours, from 5.00 hours to 6.50 hours, or from 5.50 hours to 6.00 hours. In some embodiments, the reaction time is from 0.10 hours to 2.00 hours, such as from 0.50 hours to 1.50 hours, or 1.00 hour.
Methods for preparing phosphine-borane complexes from aryldihalophosphine, according to embodiments, comprise mixing NaBH4, a solvent comprising at least 50 vol % DME, and aryldichlorophosphine to obtain a solution; and maintaining the solution at a reaction temperature for a duration of time to obtain the phosphine-borane complexes. In some embodiments, the aryldichlorophosphine is mono-aryldichlorophosphine. In one or more embodiments, the solvent further comprises THF.
Methods for preparing phosphine-borane complexes from aryldihalophosphine, according to embodiments, comprise obtaining a solution comprising NaBH4 suspended in a solvent comprising at least 50 vol % DME; adjusting a temperature of the solution to a reaction temperature; obtaining a combined solution by combining the solution with a second solution, wherein the second solution comprises aryldichlorophosphine and a second solvent; and maintaining the combined solution at the reaction temperature for a duration of time to obtain the phosphine-borane complexes. In some embodiments, the aryldichlorophosphine is mono-aryldichlorophosphine. In one or more embodiments, the solvent further comprises THF. The second solvent may, in embodiments, comprise THF.
According to embodiments the conversion of the aryldihalophosphine in a solution comprising NaBH4 and at least 50 vol % glycol ethers to arylphosphine-borane complexes is at least 90%, such as at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. In some embodiments, the conversion of the aryldihalophosphine in a solution comprising NaBH4 and at least 50 vol % glycol ethers to arylphosphine-borane complexes is 100%.
Embodiments will be further clarified by the following examples.
Dichloro(2,4-dimethoxyphenylphosphine) was prepared using Friedel-Crafts reaction using anhydrous technical grade ZnCl2 as the catalyst, which was not further purified prior to the reduction reaction.
In a three-neck flask, 30 ml DME (>99% purity obtained from Sigma Aldrich) was loaded and cooled to 0° C. One gram (g) of NaBH4 solid (>98% purity powder obtained from Sigma Aldrich) was loaded into the flask, and a small temperature increase of 2° C. was observed. Subsequently, 2.46 g (8.6 millimolar (mmol)) dichloro(2,4-dimethoxyphenylphosphine) (84% purity) diluted in 8 milliliter (mL) N2 sparged DME was slowly added to the flask at a temperature ranging from 2° C. to 6° C. The mixture was maintained at 2° C. for a duration of half an hour (0.50 hours). Next, 20 ml hexane was added to the flask and more solid precipitated out. The white slurry was filtered and the solid was washed by an additional 20 ml of hexane. The filtrate turned hazy, which was then filtered again to remove the solid. The solvent was removed and led to a white solid, which was further dried in the vacuum oven at 40° C. The yield of the 2,4-dimethoxyphenylphosphine)-borane complex was 1.62 g (82%).
The 2, 4-dimethoxyphenylphosphine-borane complex was dissolved in deuterated chloroform (CDCl3) in a 5 mm NMR tube. 13C NMR experiment was performed on a Bruker Avance 400 NMR spectrometer equipped with a 10 mm C/H DUAL cryoprobe. Both inverse-gated quantitative 13C NMR and DEPT-135 experiments were performed without sample spinning. Data were processed using MNOVA software with a 1 Hz lining broadening. The following is the setup of acquisition parameters:
Standard quantitative 1H NMR experiments were performed without sample spinning on the same instrument. Data were processed using MNOVA software with a 0.5 Hz lining broadening. The following is the setup of acquisition parameters:
1H NMR spectrum is shown in
In a three-neck flask, 16 ml DME as was used in Example 1 was loaded and cooled to 0° C. and sparged with N2 for 0.50 hours. Subsequently, 0.5 g of NaBH4 solid was loaded into the flask. Then, 0.9 g (5 mmol) dichlorophenylphosphine as obtained from a commercial supplier was diluted in 4 ml N2 sparged DME was slowly added to the flask at a temperature range from 1° C. to 7° C. The mixture was maintained at 2° C. for one hour. An NMR sample obtained as outlined in Example 1 indicated the full conversion of dichloro((phenyl)phosphine to phenylphosphine-borane complex. This is evident form the single P peak on NMR graph shown in
In a three-neck flask, 15 ml of DME was loaded. Subsequently, 0.5 g of NaBH4 solid was loaded into the flask. A solution of 1.16 g (4.3 mmol) dichloro(2,4-dimethoxyphenylphosphine) (89% purity) obtained as in Example 1 in 4 ml N2 sparged DME was prepared. The dichloro(2,4-dimethoxyphenylphosphine) solution was added into mixtures of DME and NaBH4. The NaBH4 mixtures were set at 0° C., 30° C., and 60° C. After the addition of dichloro(2, 4-dimethoxyphenylphosphine) was complete, the reactions were kept at the respective temperatures for 4 hours. The resulting solutions were quenched with water, and analyzed by 31P NMR using tri(ortho-tolyl)phosphine as an internal standard. Table 1 below shows the results of this example and the effect of temperature on the preparation of phosphine-borane complexes.
As can be seen from Table 1, there is a sharp increase in percentage yield as the reaction temperature increases from 0° C. to 30° C., but the increase in percentage yield is not as pronounced as the reaction temperature increases from 30° C. to 60° C. This indicates that temperatures above 60° C. do not provide significant improvements in percentage yield. The range of yields observed at 0° C. were measured across three independent reactions.
In a three-neck flask, a total of 15 ml THF and DME was loaded at the THF to DME ratios shown in Table 2 below. Subsequently, 0.5 g of NaBH4 solid was loaded into the flask. Then, 1.16 g (4.3 mmol) dichloro(2, 4-dimethoxyphenylphosphine) (89% purity) as obtained in Example 1 and diluted in 4 ml N2 sparged THF was slowly added to the flask at 23° C. The reactions were sampled at 25 minutes and 16 hours after this THF addition was complete, and the samples were analyzed by 31P NMR. Table 2 shows the effect of the THF to DME ratio on percentage yield.
As shown in Table 2, THF to DME ratios of 3:1 and above do not provide an observable yield of 2,4-dimethoxyphenylphosphine complex, but the yield of 2,4-dimethoxyphenylphosphine complex increases significantly from a THF to DME ratio of 3:1 to a THF to DME ratio of 1:1.
NaBH4 in an appropriate amount based on desired molar ratio to 2,4-(dimethoxyphenyl)dichlorophosphine (ArPCl2) as shown in Table 3 below was added to a three-neck round bottom flask equipped with a condenser, thermometer and a septa. This flask was evacuated under vacuum and refilled with N2 three times before DME (2.27 g) was added via syringe. 5.62 g of a 17.0 weight percent (wt %) ArPCl2 stock solution (with ArPCl2 0.962 g, 4.09 mmol) was added to the vial via syringe over a period of 0.5 hour and left stirring at room temperature overnight. Table 3 shows the results of this test.
aGC yield with dodecane as internal standard;
bNMR yield
As shown in Table 3, the percentage yield of phosphine-borane complexes increases sharply as the ratio of NaBH4 to ArPCl2 increases from 1:1 to 2.2:1
It will be apparent to those skilled in the art that various modifications and variations can be made to the embodiments described herein without departing from the spirit and scope of the claimed subject matter. Thus it is intended that the specification cover the modifications and variations of the various embodiments described herein provided such modification and variations come within the scope of the appended claims and their equivalents.
This application claims priority to U.S. Application Ser. No. 62/734,500 filed on Sep. 21, 2018, the entire disclosure of which is hereby incorporated by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2019/051662 | 9/18/2019 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62734500 | Sep 2018 | US |
